Cargando…

Liver Growth Factor “LGF” as a Therapeutic Agent for Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive degenerative disorder and the most common cause of dementia in aging populations. Although the pathological hallmarks of AD are well defined, currently no effective therapy exists. Liver growth factor (LGF) is a hepatic albumin–bilirubin complex with activit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzalo-Gobernado, Rafael, Perucho, Juan, Vallejo-Muñoz, Manuela, Casarejos, Maria José, Reimers, Diana, Jiménez-Escrig, Adriano, Gómez, Ana, Ulzurrun de Asanza, Gonzalo M., Bazán, Eulalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730107/ https://www.ncbi.nlm.nih.gov/pubmed/33276671 http://dx.doi.org/10.3390/ijms21239201

Ejemplares similares

Neuroprotective Role of Liver Growth Factor “LGF” in an Experimental Model of Cerebellar Ataxia
por: Calatrava-Ferreras, Lucía, et al.
Publicado: (2014)

Liver Growth Factor (LGF) Upregulates Frataxin Protein Expression and Reduces Oxidative Stress in Friedreich’s Ataxia Transgenic Mice
por: Calatrava-Ferreras, Lucía, et al.
Publicado: (2016)

Immunohistochemical Study of ASC Expression and Distribution in the Hippocampus of an Aged Murine Model of Alzheimer’s Disease
por: Reimers, Diana, et al.
Publicado: (2021)

Liver Growth Factor Induces Glia-Associated Neuroprotection in an In Vitro Model of Parkinson´s Disease
por: Gonzalo-Gobernado, Rafael, et al.
Publicado: (2020)

Liver Growth Factor as a Tissue Regenerating Factor in Neurodegenerative Diseases
por: Gonzalo-Gobernado, Rafael, et al.
Publicado: (2014)

Optimal excitation and emission wavelengths to analyze amino acids and optimize neurotransmitters quantification using precolumn OPA-derivatization by HPLC
por: Perucho, J., et al.
Publicado: (2015)

Effects of Intravenous Administration of Human Umbilical Cord Blood Stem Cells in 3-Acetylpyridine-Lesioned Rats
por: Calatrava-Ferreras, Lucía, et al.
Publicado: (2012)

Neuroprotective Activity of Peripherally Administered Liver Growth Factor in a Rat Model of Parkinson’s Disease
por: Gonzalo-Gobernado, Rafael, et al.
Publicado: (2013)

Flame-retardant properties and mechanism of LGF/PBT/DOPO-HQ-conjugated flame-retardant composites
por: Sun, Junzhuo, et al.
Publicado: (2022)

Fatigue Behaviour and Its Effect on the Residual Strength of Long-Fibre-Reinforced Thermoplastic PP LGF30
por: Witzgall, Christian, et al.
Publicado: (2023)

Striatal Infusion of Glial Conditioned Medium Diminishes Huntingtin Pathology in R6/1 Mice
por: Perucho, Juan, et al.
Publicado: (2013)

Multitarget drugs as potential therapeutic agents for alzheimer’s disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors
por: González-Naranjo, Pedro, et al.
Publicado: (2022)

α-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer’s disease
por: Agüero, Pablo, et al.
Publicado: (2020)

Fusion of High Resolution Multispectral Imagery in Vulnerable Coastal and Land Ecosystems
por: Ibarrola-Ulzurrun, Edurne, et al.
Publicado: (2017)

Role of Mesenchymal Stromal Cells as Therapeutic Agents: Potential Mechanisms of Action and Implications in Their Clinical Use
por: Jimenez-Puerta, Gonzalo José, et al.
Publicado: (2020)

Mechanisms Involved in Epileptogenesis in Alzheimer’s Disease and Their Therapeutic Implications
por: Altuna, Miren, et al.
Publicado: (2022)

Pyramidal cell axon initial segment in Alzheimer´s disease
por: Antón-Fernández, Alejandro, et al.
Publicado: (2022)

Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches
por: Tibbo, Amy J., et al.
Publicado: (2019)

Trehalose Improves Human Fibroblast Deficits in a New CHIP-Mutation Related Ataxia
por: Casarejos, Maria Jose, et al.
Publicado: (2014)

Trehalose Reverses Cell Malfunction in Fibroblasts from Normal and Huntington's Disease Patients Caused by Proteosome Inhibition
por: Fernandez-Estevez, Maria Angeles, et al.
Publicado: (2014)

Repaglinide Induces ATF6 Processing and Neuroprotection in Transgenic SOD1G93A Mice
por: Gonzalo-Gobernado, Rafael, et al.
Publicado: (2023)

Resveratrol as a Therapeutic Agent for Alzheimer's Disease
por: Ma, Teng, et al.
Publicado: (2014)

Neuroprotective Effects of Diets Containing Olive Oil and DHA/EPA in a Mouse Model of Cerebral Ischemia
por: Gonzalo-Gobernado, Rafael, et al.
Publicado: (2019)

Characterization of a CholesteroNitrone (ISQ-201), a Novel Drug Candidate for the Treatment of Ischemic Stroke
por: Martínez-Alonso, Emma, et al.
Publicado: (2020)

SARS-CoV-2 Prevalence in Laparoscopic Surgery Filters. Analysis in Patients with Negative Oropharyngeal RT-qPCR in a Pandemic Context: A Cross-Sectional Study (†)
por: Llueca, Antoni, et al.
Publicado: (2021)

Anti-N-Methyl-D-Aspartate Encephalitis as Paraneoplastic Manifestation of Germ-Cells Tumours: A Cases Report and Literature Review
por: Rita, Claudia Geraldine, et al.
Publicado: (2019)

Workplace violence against healthcare workers: an observational study in Castilla y León (Spain)
por: López-Gobernado, Miguel, et al.
Publicado: (2020)

Abediterol, a novel long-acting β(2)-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD
por: Beier, Jutta, et al.
Publicado: (2016)

Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches
por: Morales, Inelia, et al.
Publicado: (2014)

Phospho-Tau Changes in the Human CA1 During Alzheimer’s Disease Progression
por: Regalado-Reyes, Mamen, et al.
Publicado: (2019)

A Multi-Agent System Architecture for Sensor Networks
por: Fuentes-Fernández, Rubén, et al.
Publicado: (2009)

Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease
por: Rizvi, Syed Mohd. Danish, et al.
Publicado: (2015)

New therapeutic strategy for Alzheimer's disease using antidiabetes agents
por: Yokono, Koichi
Publicado: (2013)

MicroRNAs in Alzheimer’s Disease: Diagnostic Markers or Therapeutic Agents?
por: Angelucci, Francesco, et al.
Publicado: (2019)

Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
por: Beggiato, Sarah, et al.
Publicado: (2019)

Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease
por: Boyarko, Ben, et al.
Publicado: (2023)

Exploiting the Chalcone Scaffold to Develop Multifunctional Agents for Alzheimer’s Disease
por: Rampa, Angela, et al.
Publicado: (2018)

Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
por: Dwomoh, Louis, et al.
Publicado: (2022)

Obesity as a Risk Factor for Dementia and Alzheimer’s Disease: The Role of Leptin
por: Flores-Cordero, Juan Antonio, et al.
Publicado: (2022)

Holmium(III) Single-Ion Magnet for Cryomagnetic Refrigeration Based on an MRI Contrast Agent Derivative
por: Rodríguez-Barea, Borja, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9merbdvtt2bfu9q089in8hf8d1